 |
인쇄하기
취소
|
KFDA Issues Revised Market Approval Specification for Gemzar
The Korea Food and Drug Administration (KFDA) recently issued a revised approval specification for Lilly Korea's Gemzar Inj. 200mg (active ingredient: gemcitabine hydrochloride), a chemotherapy drug for treatment of certain cancer types, including pancreatic cancer.
The revised specification is based on the four-year postmarketing clinical findings on 621 domestic patients with pancreatic ca...
The revised specification is based on the four-year postmarketing clinical findings on 621 domestic patients with pancreatic ca...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.